IRRADIaTE was never conceived as an incidence study. It was designed to answer a more pragmatic and practice-oriented question: what happens when late RT-related GU toxicity becomes severe enough to require urgent or inpatient urological care? That distinction is central.
A denominator-free registry—by design.
IRRADIaTE enrolled 321 men who presented with late (>6 months) GU complications attributed to prostate RT and requiring urgent evaluation or hospitalization. As clearly stated in the manuscript, the registry includes only symptomatic patients and therefore cannot provide population-level incidence estimates. This has been one of the main criticisms—and it is correct. But IRRADIaTE was intentionally outcome-dependent. In many healthcare systems, including Italy’s, post-RT complications are frequently managed outside radiation oncology departments. Nationwide administrative datasets capable of linking primary RT delivery with subsequent cross-institutional admissions are lacking. Single-center experiences are insufficient due to patient mobility. Within this context, a case-only registry becomes not a methodological flaw, but a pragmatic tool. IRRADIaTE does not tell us how often severe toxicity occurs. It tells us what severe toxicity looks like when it occurs. And that picture is clinically meaningful.
The burden within the symptomatic cohort
Among men presenting for care, 43% had CTCAE grade 3–5 toxicity at admission. Hospitalization-free survival declined from 86% at 12 months to 42% at 60 months after RT. The proportion of patients avoiding major surgery decreased from 81% at 12 months to 66% at 60 months. These figures do not represent risk in all irradiated patients. They represent the clinical trajectory in those who cross the threshold into severe morbidity.
What emerges is a pattern that many urologists recognize: late GU toxicity is often delayed, progressive, recurrent, and resource-intensive. Endoscopic management is common; reinterventions are frequent; hospital admissions accumulate over time. The Kaplan-Meier curves are not inferential for incidence, but they are qualitatively informative about timing and progression. Severe events are rarely immediate. They often manifest years later. That temporal pattern has implications for survivorship care.
The primary RT versus the postoperative RT signal
Another source of controversy has been the observation of higher cumulative severe-event signals in patients treated with primary RT compared to those receiving adjuvant or salvage RT after radical prostatectomy. We have repeatedly emphasized—both in the manuscript and in our replies to the letters to the editor received—that this comparison was not prespecified, was exploratory, and is subject to confounding by indication. Patients receiving primary RT were significantly older and more comorbid. Multivariable adjustment cannot eliminate residual confounding in this context. These findings are associational, not causal. However, dismissing the signal entirely would also be premature. From a pathophysiological perspective, the presence of an irradiated prostate in situ may plausibly contribute to obstructive symptoms, infections, hematuria, or fistulas in susceptible individuals. The hypothesis is biologically coherent. It requires denominator-based, causal-inference designs to be tested rigorously. IRRADIaTE generates hypotheses. It does not settle comparative toxicity debates.
Legacy radiotherapy and the long tail of toxicity
A substantial proportion of toxicities captured likely reflects treatments delivered years ago, often with technologies now considered outdated. Modern image guidance, refined dose constraints, and hypofractionated schedules are expected to improve toxicity profiles. Yet survivorship clinics today are treating the consequences of “legacy RT.” As prostate cancer survival improves and life expectancy increases, the pool of aging survivors exposed to earlier techniques grows. Even if contemporary RT proves safer, the healthcare system must still manage the long tail of late effects. IRRADIaTE is, therefore, a snapshot of current clinical demand generated by past treatments.
Trials, registries, and the numerator problem
Randomized trials remain the gold standard for estimating comparative toxicity risk within defined cohorts. They are denominator-based and methodologically robust. However, severe late GU events are often managed years after the trial follow-up window closes and may occur outside radiation oncology services. The denominator in trials is precise; the numerator of severe, resource-intensive urological events may be less completely captured in long-term real-world practice. IRRADIaTE approaches the question from the opposite direction: it captures the numerator of clinically consequential events, without a denominator. Neither perspective is sufficient alone. Together, they are complementary.
The core message: survivorship integration
If IRRADIaTE has a central message, it is not that one modality is superior to another. It is that survivorship care remains fragmented. Radiation oncology departments often lack inpatient wards. Urological departments manage many late complications. Communication between specialties is variable. As the number of elderly and frail survivors increases, complex late GU morbidity will inevitably become more common. Shared decision-making should address not only oncologic control and early functional outcomes, but also the potential for delayed, sometimes invasive sequelae. Follow-up after RT should extend beyond PSA surveillance and incorporate a structured urological assessment in aging patients.
Moving forward
IRRADIaTE does not provide incidence. It does not provide causal comparisons. It does not challenge the established efficacy of radiotherapy. It provides a clinically grounded, prospective description of what severe late GU toxicity looks like in daily practice across 20 Italian centers. The controversy it generated is, in many ways, healthy. It highlights the need for:
- denominator-based, multicenter administrative linkage studies
- standardized long-term toxicity capture across specialties
- integrated survivorship pathways
- and transparent, balanced patient counseling
Ultimately, the goal is not to defend a registry. It is to ensure that, as prostate cancer outcomes improve, the long-term quality of survival receives equal attention. We believe IRRADIaTE was one step in that direction.
- AOUI Verona, University of Verona, Verona, Italy
Read the Abstract